The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) in treating EGFR mutant advanced lung cancer has been established [7] Furthermore, attempts are being made to explore the use of EGFR-TKIs as adjuvant therapy for earlier stages of lung cancer. Here, EGFR is linked to lung carcinoma.